LETTER TO EDITOR

CaMKII, that binds with ligustilide, as a potential drug target of Suxiao jiuxin pill, a traditional Chinese medicine to dilate thoracic aorta

Dear Editor,

Vasodilation is one of the main means to treat cardiovascular diseases, such as heart failure, cardiogenic shock and severe hypertension.1 Although blocking voltage-gated calcium channels with specific antagonists stands as an optimal therapeutic strategy, 2 targeting Ca2+/calmodulin-dependent protein kinase II (CaMKII) may also be a suitable approach, as this enzyme also plays an important role in the regulation of Ca2+-related physiological functions3,4 and cardiovascular diseases.5,6 Herein, we reveal a novel mechanism of CaMKII covalent inhibition by one kind of the phthalides present in Suxiao Jiuxin pills (SX), a traditional Chinese medicine frequently used for the treatment of cardiovascular disease.

A head-to-head randomized clinical comparison of SX and atorvastatin calcium (At-Ca) in patients with atherosclerosis showed that SX significantly increased cardiac output, while At-Ca mainly lowered lipid overload, indicating that these compounds ameliorate clinical symptoms through different mechanisms (Figure 1A–H, Tables S1 and S2). SX treatment does not affect heart rate and has little effect on myocardial contractility, so it may increase cardiac output by dilating the thoracic aorta (Figures S1, S2). To identify the potential vasodilator targets of SX, a cellular thermal shift assay (CETSA) coupled with iTRAQ-based differential proteomic analysis was performed. The abundance of 199 unique proteins (among which 142 were upregulated and 57 were downregulated) was significantly altered after exposure to SX (Figure 1I). Among them, only one potential target protein was identified, namely, CaMKIIδ which participates in cardiovascular contraction by regulating the calcium signalling pathway (Figure 1J–L). Additionally, CETSA results demonstrated that the SX extract effectively improved the thermal stability of CaMKII in human vascular smooth muscle cells (VSMCs; Figure 1M).

Subsequently, ultra-performance liquid chromatography coupled with CaMKII-mediated calcium antagonist screening was conducted to identify the active pharmaceutical ingredient in SX (Figure 2A). The results revealed that the two major components of SX, ligustilide (Lig) and senkyunolide A (Sen A), exhibited Ca2+-inhibitory activity by acting on CaMKII (Figures 2B, S3). Because Lig was more abundant in SX than Sen A (Figure S4, Table S3), an alkynyl-modified Lig probe and its fluorophore tracer were synthesized and used to verify the interaction between Lig and CaMKII (Figures 2C, S5–S9). VSMCs staining showed that the fluorescence of the Lig-modified tracer partly overlapped with that of the CaMKII antibody, while the overlapping position could be replaced by 10-fold free Lig and Sen A competition (Figures 2D, S10). Moreover, an in-gel imaging assay of 293T cells overexpressing CaMKII and VSMCs indicated that phthalides with double bonds at the C6/C7 might be the key pharmacophores involved in the covalent binding to CaMKII (Figure 2E,F). Furthermore, CETSA results indicated that Lig and Sen A had a similar effect on CaMKII, whereas senkyunolide I (Sen I) had no significant effect (Figure 2G).

In humans, four subtypes of CaMKII share the N-terminal catalytic/autoregulatory domain and a C-terminal association domain, which is necessary for the assembly of the CaMKII holoenzyme complex (Figure 3A).7,8 To identify the binding site of Lig in CaMKII, the recombinant wild-type human CaMKIIγ protein (residues 1–271) was expressed and purified (Figure S11), then simultaneously incubated with Lig probe and liver tissue lysates. The results of the in-gel imaging assay revealed that only Lig and Sen A covalently bound to CaMKII after liver metabolism (Figures 3B, S12, S13). It is well-established that the C6/C7 double bond of Lig is metabolized into an epoxy group in vivo.9,10 Protein mass spectrometry identification revealed that the
FIGURE 1 The clinical efficacy evaluation of Suxiao Jixiu pills (SX) and differential proteomics assay for identifying the potential target in vasodilator activity. (A–E) Patients treated with SX (40 mg a pill, 6 pills a time, three times a day, sublingually) or atorvastatin calcium tablets (At-Ca, 10 mg tablet a time, once a day, orally) for 2 weeks underwent routine blood examination, including neutrophils (NEUT), lymphocytes (LYMPH), and the ratio of neutrophils to lymphocytes (NEUT/LYMPH), and blood lipid examination including low-density lipoprotein (LDL) and total cholesterol (TC) contents, before and after treatment (n = 50). (F–H) The cardiac output (CO), fraction shortening (FS), and ejection fraction (EF) of patients were measured using colour Doppler echocardiography (n = 10). (I) Volcanic map of the quantitative proteins identification by cellular thermal shift assay (CETSA) combined with iTRAQ-based proteomic analysis in human vascular smooth muscle cell (VSMCs) lysates treated with SX extract (1 mg/ml). (J) Top 10 significantly enriched pathways using the Kyoto Encyclopaedia of Genes and Genomes (KEGG) database. (K) Venn diagram analysis of SX targets in relaxing cardiovascular activity. The red intersection is the common target CaMKIIδ (gene name: CAMK2D). (L) The heat map of cluster analysis illustrates the iTRAQ results of six contraction or cardiovascular-related proteins. (M) SX extract (1 mg/ml) treatment increased the thermal stability of CaMKII in VSMCs as measured by temperature (left panel) or dose (right panel) dependent CETSA (n = 3). *p < .05 and **p < .01 compared with baseline; ***p < .001 compared between two groups by a two-sided Student’s t-test.
Phthalides with C6/C7 double bonds in Suxiao Jixun pills (SX) are the key compounds for CaMKII inhibition. (A) UPLC combined with dual-luciferase reporter assays was used to screen the CaMKII-dependent calcium antagonists from SX extract (n = 3). The 293T cells were co-transfected with CaMKIIG plasmid, Ca2+ luciferase reporter plasmid PGL4.30, and Renilla luciferase plasmid (50:25:1, m/m/m) for 22 h. The cells were stimulated with ionomycin (1 mM) and phorbol 12-myristate 13-acetate (1 mg/mL) for 6 h, and simultaneously treated with drugs. (B) Confirmatory test of active pharmaceutical ingredient (API) for intracellular calcium inhibition activity, and CaMKII competitive inhibitor KN-93 as a positive control (n = 5). (C) Chemical structure of Lig probe and its fluorescent tracer, which conjugated with boron-dipyrromethene tetramethylrhodamine (BDP TMR) azide via click reaction. (D) Co-localization of CaMKII (pseudo red) and Lig probe (pseudo green) in VSMCs. The distribution of merged yellow in the Lig probe group could be partial replaced by 10-fold free Lig competition, the Pearson coefficient (PC) value dropped from ∼0.91 to ∼0.32. (E and F) In-gel imaging analysis for CaMKII protein labelled with Lig probe and BDP TMR tracer (upper panel) in the 293T cells with over-expression of CaMKII or VSMCs. Western blot was used as a control of CaMKII protein (lower panel). The cells were all treated with Lig probe (1 μM) in the absence or presence of 10 μM competitive agents, including Lig, Sen A or Sen I. (G) The thermal stability of CaMKII at 53°C in VSMCs treated with different doses of Lig, Sen A and Sen I (0.3, 0.6, 1.25, 2.5, 5, 10 and 20 μM) was measured with dose-dependent CETSA (n = 3). Bars represent the mean ± SD. **p < .01 and ***p < .001 compared with the control group by a two-sided Student’s t-test. **p < .01 and ***p < .001 compared with the model group by one-way analysis of variance (ANOVA).
**FIGURE 3** E-Lig covalently binds to CaMKII at Cys116 via nucleophilic addition. (A) Comparison of the main sequences of human members of the CaMKII family. (B) The C6/C7 double bond of Lig was proposed to be a major pharmacophore for Lig binding to CaMKII. Recombinant CaMKIIγ was co-incubated with Lig probe in the absence or presence of Lig, Sen A and Sen I (10 μM) at 4°C for 12 h under the catalysis of liver tissue lysates, and the products were used for in-gel imaging. (C) LC–MS/MS analysis of the recombinant CaMKIIγ protein incubated with E-Lig for 12 h. E-Lig binds to the Cys116 residue of CaMKIIγ. (D) The proposed covalent binding mode of Lig to CaMKII (left panel). And molecular modelling of E-Lig covalently bound to the Cys116 of CaMKIIγ (PDB: 2V70) (right panel). E-Lig is displayed in sticks and coloured by atomic type, in which the carbon atom is gray. The group that reacted with Cys116 of CaMKIIγ is shown in yellow. (E) In-gel imaging of wild-type CaMKIIγ and the two mutants (C116G and C148G). The proteins were incubated with the Lig probe (1 μM) catalysed by liver tissue lysates at 4°C for 12 h. (F) E-Lig metabolite increased the thermal stability of wild-type CaMKIIγ but had no effect on the C116G mutant, as measured by thermal shift assay (n = 3). (G) The calcium antagonistic activity of the compound was determined in 293T cells with high expression of CaMKIIγ_C116G protein. Bars represent the mean ± SD. ***p < .001 compared with the control group by a two-sided Student's t-test. ****p < .001 compared with the model group by one-way analysis of variance (ANOVA)
FIGURE 4  Lig alleviates vascular and cardiac dysfunction by specifically inhibiting the phosphorylation of CaMKII in VSMCs of thoracic aorta after metabolism to epoxide. (A) The cardiac output (CO), fraction shortening (FS) and ejection fraction (EF) were measured in...
epoxidised metabolite 7-epoxyligustilide (E-Lig) attacks the thiol group of Cys116 on the CaMKII catalytic domain (Figure 3C). Molecular docking indicated that the epoxy group of E-Lig was destroyed, followed by a nucleophilic addition interaction at Cys116 of CaMKIIγ. Meanwhile, the newly formed hydroxyl group established stable hydrogen bond interactions with the Asp-112 and His-115 residues (Figure 3D).

Moreover, CaMKIIγ protein with mutated cysteine residues (C116G and C148G) was utilized to test this hypothesis by in-gel imaging assays. As predicted, E-Lig selectively covalently bound to Cys116 independently of Cys148 (Figure 3E). Thermal stability analysis also supported that only the metabolite of Lig (E-Lig) could covalently bind to CaMKII at Cys116, suggesting this residue may be a druggable site (Figures 3F, S14). Once the Cys116 residue was destroyed, the calcium antagonistic activity of Lig and Sen A in 293T cells overexpressing C116G protein also disappeared (Figures 3G, S15).

To verify the vasodilator effect of Lig in vivo, transthoracic echocardiography was performed to detect the degree of systolic dysfunction in atherosclerotic ApoE−/− mice. Lig treatment effectively reversed the decrease in cardiac output and increased fractional shortening and ejection fraction in a dose-dependent manner (Figures 4A, S16). Co-localization imaging of living tissues revealed that the oral Lig probe mainly targeted CaMKII in the VSMCs of the thoracic aorta (Figure 4B). After oral administration of Lig, the relative fluorescence intensity of phosphorylated CaMKII in the thoracic aorta decreased significantly (Figure 4C). In addition, an experiment with KCl-induced isolated rat thoracic aortic ring indicated that Lig exerts a dramatic vasodilatory effect by inhibiting CaMKII autophosphorylation and its downstream myosin light chain phosphorylation (Figures 4D, E, S17).

Next, the benefit of the covalent bound between E-Lig and CaMKII on the vasodilator activity was evaluated using an isolated aortic ring test. The vasodilator effect of E-Lig was significantly stronger than that of Lig at the same dose. Remarkably, the effect could be suppressed by a reducing environment (Figure 4F), because the addition of vitamin C (Vc) inhibited the generation of the epoxidised metabolites, both in the Lig and SX extracts. Compared with the CaMKII competitive inhibitor KN-93, the irreversible binding of E-Lig was more enduring for vasodilator activity (Figure 4G).

In conclusion, as a key active component of SX, the epoxidised metabolite of Lig covalently binds to the Cys116 of CaMKII in VSMCs of the thoracic aorta, inhibits the autophosphorylation of CaMKII, and exerts a long-lasting vasodilator effect. Our findings reveal a novel mechanism of inhibiting CaMKII phosphorylation via a nucleophilic addition reaction, providing insights into the development of a potentially promising drug for the treatment of cardiovascular diseases.

ACKNOWLEDGEMENTS
This research was supported by the National Natural Science Foundation of China (Nos. 81673637), and National Key Research and Development Program of China (Nos. 2018YFC1704805).

CONFLICT OF INTEREST
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Molecular Drug Research, Nankai University, Tianjin, China
2 First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
3 National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China
4 Tianjin University of Traditional Chinese Medicine, Tianjin, China

Correspondence
Min Jiang, State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China.
E-mail: minjiang@nankai.edu.cn

Gang Bai, State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China.
E-mail: gangbai@nankai.edu.cn

#YuJie Lu and Jie Ji contributed equally to this work.
Letter-to-Editor with submission number: CTM2-2022-02-0360

ORCID
Gang Bai https://orcid.org/0000-0001-9161-2173

REFERENCES
1. Viau DM, Sala-Mercado JA, Spranger MD, et al. The pathophysiology of hypertensive acute heart failure. Heart. 2015;101(23):1861-1867.
2. Zuccotti A, Clementi S, Reinbothe T, et al. Structural and functional differences between L-type calcium channels: Crucial issues for future selective targeting. Trends Pharmacol Sci. 2011;32(6):366-375.
3. Prasad AM, Nuno DW, Koval OM, et al. Differential control of calcium homeostasis and vascular reactivity by Ca(2+)/calmodulin-dependent kinase II. Hypertension. 2013;62(2):434-441.
4. Wehrens XH, Lehnart SE, Reiken SR, et al. Ca(2+)/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res. 2004;94(6):e61-70.
5. Mustroph J, Drzymalski M, Baier M, et al. The oral Ca(2+)/calmodulin-dependent kinase II inhibitor RA608 improves contractile function and prevents arrhythmias in heart failure. ESC Heart Fail. 2020;7(5):2871-2883.
6. Bezzerides VJ, Caballero A, Wang S, et al. Gene therapy for catecholaminergic polymorphic ventricular tachycardia by inhibition of Ca(2+)/calmodulin-dependent kinase II. Circulation. 2019;140(5):405-419.
7. Rosenberg OS, Deindl S, Sung RJ, et al. Structure of the autoinhibited kinase domain of CaMKII and SAXS analysis of the holoenzyme. Cell. 2005;123(5):849-860.
8. Rellos P, Pike AC, Niesen FH, et al. Structure of the CaMKIIδ/calmodulin complex reveals the molecular mechanism of CaMKII kinase activation. PLoS Biol. 2010;8(7):e1000426.
9. Duan F, Xu W, Liu J, et al. Preparing the key metabolite of Z-ligustilide in vivo by a specific electrochemical reaction. J Sep Sci. 2018;41(13):2799-2807.
10. Yan R, Ko NL, Li SL, et al. Pharmacokinetics and metabolism of ligustilide, a major bioactive component in Rhizoma Chuanxiong, in the rat. Drug Metab Dispos. 2008;36(2):400-408.

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Lu Y, Ji J, Chu S, et al. CaMKII, that binds with ligustilide, as a potential drug target of Suixiaojuxin pill, a traditional Chinese medicine to dilate thoracic aorta. Clin Transl Med. 2022;12:e907.
https://doi.org/10.1002/ctm2.907